Clinical Trial Update: Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) [Phase 1]

View source ↗

Summary

Phase 1 safety and dose study of GRN163L (imetelstat) in patients with chronic lymphoproliferative diseases; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoproliferative Diseases

Drugs mentioned

• GRN163L (imetelstat) (imetelstat)

Snippet

Sponsor: Geron Corporation | Conditions: Chronic Lymphoproliferative Diseases | Phase 1 | Status: COMPLETED